Sunday, June 22, 2025 12:55:08 AM
Mani, I don't think IND's will be submitted on new trials until UK approval is in. I believe that the IND has a 60 day presumptive acceptance, then the IRB of the lead clinicians hospital must finalize the trial protocol, that can take a few months. If we don't get UK approval in the next month or two, unless a filing is made prior to the approval, it might not be possible to start this year, even if that's what they wanted to do.
I don't believe the company thought the UK would take this long when LP did her Annual Meeting nearly a year ago. I don't believe we'll get another meeting until we get the answer from the UK. I still believe that LP will have much to announce during the remainder of the year, but some things they hoped would be initiated this year may not be initiated till next.
I'm hoping we gain EDEN approval ASAP, I still believe it's the key to filing with regulators everywhere and none of that will occur until the company at least believes it's no more than a few months away.
If things go well between now and the end of the year I'd hope that we'll have filed for approval of DCVax-L elsewhere by the end of the year. I believe that we've learned much from the UK filing and all that's been learned needs to be incorporated into the 1.7 million pages that were submitted to the UK so the same questions never come up again. No doubt there will be new questions, but we shouldn't need to deal with any of the old ones again.
Gary
I don't believe the company thought the UK would take this long when LP did her Annual Meeting nearly a year ago. I don't believe we'll get another meeting until we get the answer from the UK. I still believe that LP will have much to announce during the remainder of the year, but some things they hoped would be initiated this year may not be initiated till next.
I'm hoping we gain EDEN approval ASAP, I still believe it's the key to filing with regulators everywhere and none of that will occur until the company at least believes it's no more than a few months away.
If things go well between now and the end of the year I'd hope that we'll have filed for approval of DCVax-L elsewhere by the end of the year. I believe that we've learned much from the UK filing and all that's been learned needs to be incorporated into the 1.7 million pages that were submitted to the UK so the same questions never come up again. No doubt there will be new questions, but we shouldn't need to deal with any of the old ones again.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
